Home Health GSK to buy US cancer treatment firm Nuvalent for $10.6bn
Health

GSK to buy US cancer treatment firm Nuvalent for $10.6bn

Key Points

British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share...

British drugmaker’s new chief executive Luke Miels announces one of its biggest deals

GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.

The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share in cash.

Continue reading...
GSK (ORG) US (LOCATION) Nuvalent (LOCATION) British (ORG) drugmaker (ORG) Luke Miels (PERSON) FTSE (ORG) Boston (LOCATION)
Originally published by The Guardian Business Read original →